Mariya Rozenblit, MD
Assistant Professor of Medicine (Medical Oncology)Cards
About
Titles
Assistant Professor of Medicine (Medical Oncology)
Biography
Dr. Mariya Rozenblit is an Assistant Professor of Medicine in the section of Medical Oncology and cares for patients with a clinical focus on breast cancer. She completed her Fellowship in Medical Oncology-Hematology at Yale, Residency in Internal Medicine at NYU, and received her medical degree from Icahn School of Medicine. She is involved in educating medical students, residents, and fellows at Yale. Outside of the clinic, her focus is translational research with an interest in biomarker driven trial development in breast cancer.
In 2020, she was the recipient of the ASCO Conquer Cancer Foundation Young Investigator Award for her project, “Using single nucleotide variants of high functional importance to predict the risk of developing breast cancer in young women with high risk family history.” This award is for promising investigators to encourage and promote quality research in clinical oncology. In 2022, she was the recipient of the Susan G. Komen Career Catalyst Research Grant for her project, "Curing de novo oligometastatic HER2+ breast cancer". This grant is to foster promising breast cancer researchers by providing support for up to three years.
Last Updated on May 22, 2025.
Appointments
Medical Oncology and Hematology
Assistant ProfessorPrimary
Other Departments & Organizations
- All Institutions
- Center for Breast Cancer
- Genomics, Genetics, and Epigenetics
- Internal Medicine
- Medical Oncology and Hematology
- Palade House Affiliates
- Yale Cancer Center
- Yale Medicine
- Yale New Haven Health System
Education & Training
- Fellowship
- Yale University School of Medicine (2021)
- Internal Medicine Resident
- NYU Langone Medical Center (2018)
- MD
- Icahn School of Medicine at Mount Sinai (2015)
- BA
- Columbia University, Biology (2009)
Research
Publications
2026
Current Management Practices of De Novo Oligometastatic Breast Cancer: Real-World Data From a Physician Survey.
Odzer N, Wei W, Lustberg M, Pusztai L, Rozenblit M. Current Management Practices of De Novo Oligometastatic Breast Cancer: Real-World Data From a Physician Survey. JCO Oncology Practice 2026, op2500413. PMID: 41616223, DOI: 10.1200/op-25-00413.Peer-Reviewed Original ResearchOligometastatic breast cancerMetastatic breast cancerBreast cancerMedical oncologistsSurgical resectionAblative radiationHuman epidermal growth factor receptor 2-positiveEpidermal growth factor receptor 2-positiveResponse to initial chemotherapyOptimal managementPractice patternsHER2+ diseaseTriple-negative diseasePalliative systemic chemotherapyPrimary breast tumorsCurative-intent therapyTreatment of de novoManagement of de novoUS medical oncologistsSystemic chemotherapyReceptor-positiveInitial chemotherapyPrimary tumorResidual lesionsReceptor subtypesMutational landscape of normal breast tissues adjacent to invasive breast cancer
Suwalska A, Rozenblit M, Harigopal M, Dai J, Liu M, Townsend J, Marczyk M, Pusztai L. Mutational landscape of normal breast tissues adjacent to invasive breast cancer. Cell Reports Medicine 2026, 7: 102543. PMID: 41512875, PMCID: PMC12866091, DOI: 10.1016/j.xcrm.2025.102543.Peer-Reviewed Original ResearchConceptsNormal breast tissueBreast cancerSingle-base substitutionsHistory of breast cancerSomatic mutationsBreast tissueSamples of peripheral bloodCancer-adjacent normal breast tissueCancer-predisposing genesCancer hallmark pathwaysCancer-related genesYears of agePeripheral bloodCancer-relevant pathwaysImpact of variantsNormal breastGermline mutationsMalignant transformationMutation profilesCancer riskIndependent cohortHallmark pathwaysCancerTissue typesRare polymorphism
2025
HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer
Lee S, Kahn A, Rozenblit M, George M, Ortiz C, Lustberg M. HER2‐Targeted Antibody‐Drug Conjugate Toxicities in Breast Cancer. Cancer Medicine 2025, 14: e71415. PMID: 41361931, PMCID: PMC12685761, DOI: 10.1002/cam4.71415.Peer-Reviewed Original ResearchConceptsHER2-targeting antibody-drug conjugateAntibody-drug conjugatesBreast cancerTrastuzumab deruxtecanTrastuzumab emtansineAdverse eventsDose-limiting toxicityAssociated with epistaxisSecond-line agentsSerious adverse eventsGastrointestinal adverse effectsBreast cancer outcomesOrgan-specific adverse eventsAssociated with alopeciaDose escalationClinical benefitTherapeutic dosesDecreased appetiteTherapeutic efficacyClinical trialsTrastuzumabCancer outcomesBreastCancerDeruxtecanPrognostic Value of Circulating Tumor DNA in HR+/HER2− Stage I–III Breast Cancer: A Systematic Review
Ajjawi I, Rozenblit M, Rios-Hoyo A, Lustberg M. Prognostic Value of Circulating Tumor DNA in HR+/HER2− Stage I–III Breast Cancer: A Systematic Review. Cancers 2025, 17: 2831. PMID: 40940926, PMCID: PMC12427406, DOI: 10.3390/cancers17172831.Peer-Reviewed Original ResearchCirculating tumor DNAInvasive disease-free survivalCirculating tumor DNA detectionDisease-free survivalHR+/HER2- breast cancerBreast cancerPrognostic valueSurvival outcomesTumor DNAPrognostic value of circulating tumor DNARisk of late recurrenceHER2-negative breast cancerSystematic reviewAssociated with inferior survival outcomesCirculating tumour DNA assaysStage I-III breast cancerEarly-stage breast cancerHormone receptor-positiveDetection of circulating tumor DNAMinimal residual diseaseRecurrence-free survivalI-III breast cancerInferior survival outcomesNegative prognostic markerPost-treatment surveillanceSurgeon Attitudes on the Management of de novo Oligometastatic Breast Cancer
Brennan M, Plichta J, Rozenblit M, Flanagan M. Surgeon Attitudes on the Management of de novo Oligometastatic Breast Cancer. Annals Of Surgical Oncology 2025, 32: 9478-9479. PMID: 40767935, DOI: 10.1245/s10434-025-17912-7.Peer-Reviewed Original ResearchErratum: De Novo Oligometastatic Breast Cancer
Pusztai L, Rozenblit M, Dubsky P, Bachelot T, Kirby A, Linderholm B, White J, Chmura S, Carey L, Chua B, Miller K. Erratum: De Novo Oligometastatic Breast Cancer. Journal Of Clinical Oncology 2025, 43: 2758-2758. PMID: 40690726, PMCID: PMC12521985, DOI: 10.1200/jco-25-01626.Peer-Reviewed Original ResearchQuantifying the clinical impact of tissue reflex testing for liquid biopsy ESR1 mutation–negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer.
Du J, Quintanilha J, Huang R, Heilmann A, Kahn A, Rozenblit M, Chiang A, Pusztai L, Krop I, Winer E, Graf R, Mills J, Hernandez A, Levy M, Lustberg M. Quantifying the clinical impact of tissue reflex testing for liquid biopsy ESR1 mutation–negative cases with low ctDNA tumor fraction (TF) in HR(+)HER2(-) breast cancer. Journal Of Clinical Oncology 2025, 43: 1065-1065. DOI: 10.1200/jco.2025.43.16_suppl.1065.Peer-Reviewed Original ResearchMetastatic breast cancerComprehensive genomic profilingPositive percent agreementClinicogenomic databaseTumor fractionCtDNA sheddingBC patientsReflex testBreast cancerFirst-line standard of careResistance to estrogen deprivationTissue comprehensive genomic profilingMetastatic breast cancer patientsFalse negative rateFoundationOne Liquid CDxFirst-line standardMutation-negative casesCohort of patientsStandard of careESR1 mutationsTumor genotypeEstrogen deprivationFirst-lineAromatase inhibitorsClinical impactGenomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers
Jeon J, Chen K, Madison R, Schrock A, Sokol E, Levy M, Rozenblit M, Huang R, Pusztai L. Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers. The Oncologist 2025, 30: oyaf089. PMID: 40421962, PMCID: PMC12107548, DOI: 10.1093/oncolo/oyaf089.Peer-Reviewed Original ResearchConceptsHomologous recombination deficiencyDe novo stage IV breast cancerStage IV breast cancerPrimary breast cancerIV breast cancerStage I-III cancerStage I-IIIBreast cancerGenomic alterationsFrequency of genomic alterationsHER2+ cancersI-IIITargetable genomic alterationsGenomic landscapePlatinum-based treatmentWild-type cancersHR repairCancer-related genesER+/HER2- cancersLate relapsePrimary tumorFoundation MedicinePIK3CA mutationsMutation statusNo significant differenceAccelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers
Abraham S, Parekh J, Lee S, Afrin H, Rozenblit M, Blenman K, Perry R, Ferrucci L, Liu J, Irwin M, Lustberg M. Accelerated Aging in Cancer and Cancer Treatment: Current Status of Biomarkers. Cancer Medicine 2025, 14: e70929. PMID: 40322791, PMCID: PMC12051034, DOI: 10.1002/cam4.70929.Peer-Reviewed Original ResearchConceptsBiological age of patientsLeukocyte telomere lengthInterleukin-6Treatment-related toxicityAge of patientsTherapy-induced toxicityExpression of p16INK4aPredictors of toxicityStatus of biomarkersMarkers of cellular senescenceRadiation therapyBiological ageCancer patientsCancer therapyFunctional reserveAging biomarkersPhysiological reserveCancer treatmentCancerConfirmatory studiesTherapyClinical practiceFunctional capacityPatientsFunctional statusClinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status
Lambertini M, Blondeaux E, Tomasello L, Agostinetto E, Hamy A, Kim H, Franzoi M, Bernstein-Molho R, Hilbers F, Pogoda K, Wildiers H, Bajpai J, Ignatiadis M, Moore H, Partridge A, Phillips K, Toss A, Rousset-Jablonski C, Criscitiello C, Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong S, Vernieri C, Ruddy K, Dieci M, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L, Puglisi F, Rodriguez-Wallberg K, Duhoux F, Livraghi L, Bruzzone M, Boni L, Balmaña J. Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status. Journal Of Clinical Oncology 2025, 43: 1706-1719. PMID: 39993249, PMCID: PMC12058366, DOI: 10.1200/jco-24-01334.Peer-Reviewed Original ResearchConceptsClinical behavior of breast cancerBehavior of breast cancerClinical behaviorPathogenic/likely pathogenic variantsBreast cancerBRCA2Germline pathogenic/likely pathogenic variantsDisease-free survival eventsStage I-III invasive breast cancerTime of genetic testingGermline BRCA statusHormone receptor-negativeInvasive breast cancerLower treatment burdenRetrospective cohort studyNodal involvementAxillary dissectionBRCA statusReceptor-negativeOverall survivalBRCA carriersTumor stageBreast cancer diagnosisPathogenic variantsCohort study
Clinical Trials
Current Trials
A pilot study to evaluate biomarkers and safety of dapagliflozin concomitant with neoadjuvant therapy for patient with HER2-negative early-stage breast cancer and hyperinsulinemia
IRB ID2000033529RoleSub InvestigatorPrimary Completion Date12/31/2025Recruiting ParticipantsRandomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive Breast Cancer
IRB ID2000024170RoleSub InvestigatorPrimary Completion Date01/01/2035Recruiting ParticipantsA Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
IRB ID2000029678RoleSub InvestigatorPrimary Completion Date12/15/2023Recruiting Participants
Academic Achievements & Community Involvement
Clinical Care
Overview
Mariya Rozenblit, MD, is a medical oncologist who specializes in treating patients with different types of breast cancer, from ductal carcinoma in situ (DCIS), the most common type of breast cancer, to metastatic breast cancer, or stage IV breast cancer.
Dr. Rozenblit research focuses on biomarker-driven trial development in breast cancer. These types of clinical trials allow researchers to investigate how patients (including those with different cancer mutations) respond to available medications. For example, Dr. Rozenblit co-authored a study that found patients younger than 40 with advanced breast cancer often suffer a worse prognosis and more severe symptoms than older patients.
She has received the American Society of Clinical Oncology’s Conquer Cancer Foundation’s Young Investigator Award and the Susan G. Komen Cancer Catalyst Research Grant. Dr. Rozenblit is an assistant professor of medicine (medical oncology) at Yale School of Medicine.
Clinical Specialties
Medical Oncology
Fact Sheets
Breast Cancer
Learn More on Yale MedicineCancer
Learn More on Yale MedicineDiagnosing Cancer
Learn More on Yale MedicineInflammatory Breast Cancer
Learn More on Yale Medicine
Yale Medicine News
News & Links
Media
Smilow Shares: Breast Cancer Awareness Month: Early-Stage Breast Cancer
October 9, 2025
Moderated by: Rachel Greenup, MD, MPH
Presentations by:
Elizabeth Berger, MD, MS, FACS
Mariya Rozenblit, MD
Siba Haykal, MD, PhD, FRCS, FACS
News
- December 13, 2025
Yale research advances presented at San Antonio Breast Cancer Symposium annual meeting
- October 27, 2025
YCC Publications 2025
- May 22, 2025
2025 ASCO Conquer Cancer Grants & Awards Announced
- April 08, 2025
Comprehensive Breast Cancer Care at Smilow Cancer Hospital at Greenwich and Stamford
Get In Touch
Contacts
Appointment Number
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.